Forces influencing generic drug development in the United States: A narrative review

Journal of Pharmaceutical Policy and Practice

Volumn 9, Issue 1, 2016, Pages

  Lee, Chia Ying ^a   Chen, Xiaohan ^a   Romanelli, Robert J ^b   Segal, Jodi B ^a,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b PALO ALTO MEDICAL FOUNDATION RESEARCH INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Generic drug; Incentives; U.S. Food and Drug Administration

Indexed keywords

GENERIC DRUG;

BIOEQUIVALENCE; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SAFETY; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; NARRATIVE; PATENT; PUBLIC HEALTH; REVIEW; UNITED STATES;

EID: 84995665624     PISSN: None     EISSN: 20523211     Source Type: Journal    
DOI: 10.1186/s40545-016-0079-1     Document Type: Review

References (36)

1. U.S. Department of Health & Human Services, Office of the Assistant Secretary for Planning and Evaluation. ASPE issue brief. Expanding the use of generic drugs. 2010. Retrieved from https://aspe.hhs.gov/basic-report/expanding-use-generic-drugs.
2. Anonymous, Generic Pharmaceutical Association. Generic drug savings in the U.S.: Seventh annual edition: 2015. 2015. Retrieved from http://www.gphaonline.org/media/wysiwyg/PDF/GPhA_Savings_Report_2015.pdf.
3. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products - general considerations. 2003. Retrieved from http://www.fda.gov/ohrms/dockets/ac/03/briefing/3995B1_07_GFI-BioAvail-BioEquiv.pdf.
4. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: bioavailability and bioequivalence studies submitted in NDAs or INDs - general considerations. 2014. Retrieved from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM389370.pdf.
5. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. 2013. Retrieved from http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm377465.pdf.
6. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673-83.
7. Barei F, Le Pen C, Simoens S. The generic pharmaceutical industry: moving beyond incremental innovation towards re-innovation. Generics Biosimilar J. 2013;2(1):13-9.
8. Ding M, Dong S, Eliashberg J, Gopalakrishnan A. Portfolio management in new drug development. In: Innovation and marketing in the pharmaceutical industry. New York: Springer; 2014. p. 83-118.
9. Ross MS. Innovation strategies for generic drug companies: moving into supergenerics. IDrugs. 2010;13(4):243-7.
10. Barei F, Le Pen C, Simoens S. The generic pharmaceutical industry: moving beyond incremental innovation towards re-innovation. Generics Biosimilars Initiat J. 2013;2(1):13-9.
11. Von Koeckritz K. Generic drug trends-What's next? Pharm Times. 2012;78(4):78. Retrieved from http://www.pharmacytimes.com/publications/issue/2012/april2012/generic-drug-trends-whats-next- -
12. McKinsey & Company, Global Generics Interest Group. Generating value in generics: finding the next five years of growth. 2013. Retrieved from http://www.pharmatalents.es/assets/files/generating_value.pdf.
13. Godman B, Shrank W, Andersen M, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res. 2010;10(6):707-22.
14. Chidambaram A. Global generic pharmaceutical market - Qualitative and quantitative analysis. 2013. Pharma Tech 2013 Conference. Retrieved from http://www.slideshare.net/AiswariyaChidambaram/pharma-tech-2013-aiswariya-chidambaram-fs.
15. U.S. Food and Drug Administration. Product-specific recommendations for generic drug development. 2016. Retrieved from http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075207.htm.
16. Srinivasan A. Complex generics: maximizing FDA approval potential. 2015. Retrieved from https://www.parexel.com/files/6714/3076/9385/ComplexGenerics_WPApril2015_final.pdf.
17. Sario N. Prescription drug market: the world is turning to generics. Market realist. 2015. Retrieved from http://marketrealist.com/2015/03/analyzing-prescription-market-branded-generic-drugs/.
18. Lionberger R. Complex Generic Drugs. GPhA Fall Technical Meeting, Bethesda, MD. 2013. Retrieved from http://www.fda.gov/downloads/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm374191.pdf.
19. Bowman D. A quick guide for sourcing biopharmaceutical raw materials. BioProcess international. 2015. Retrieved from http://www.bioprocessintl.com/upstream-processing/biochemicals-raw-materials/quick-guide-sourcing-biopharmaceutical-raw-materials/.
20. Shargel L, Kanfer I, editors. Generic drug product development: solid oral dosage forms. Active Pharmaceutical Ingredients. Chapter 2. New York: CRC Press; 2013. p. 19-21.
21. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health Syst Pharm. 2006;63(1):1172-93.
22. Wiske CP, Ogbechie OA, Schulman KA. Options to promote generics markets in the Unites States. JAMA. 2015;314(20):2129-30.
23. Kesselheim AS. An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences. Milbank Q. 2011;89(3):450-502.
24. Federal Trade Commission. Settlement of Cephalon pay for delay case ensures $1.2 billion in Ill-gotten gains relinquished; refunds will go to purchasers affected by anticompetitive tactics. 2015. Press release. Retrieved from https://www.ftc.gov/news-events/press-releases/2015/05/ftc-settlement-cephalon-pay-delay-case-ensures-12-billion-ill.
25. Federal Trade Commission. Agreements filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. 2013. Retrieved from https://www.ftc.gov/sites/default/files/documents/reports/agreements-filed-federal-trade-commission-under-medicare-prescription-drug-improvement-and/130117mmareport.pdf.
26. Supreme Court of the United States. Federal Trade Commission v. Actavis, Inc. October term, 2012 No. 12-416. 2013. Retrieved from http://www.supremecourt.gov/opinions/12pdf/12-416_m5n0.pdf.
27. Hemphill CS, Lemley MA. Earning exclusivity: generic drug incentives and the Hatch-Waxman Act. Antitrust Law J. 2011;77(3):947-89.
28. Mclean B. Bitter Pill Prozac made Eli Lilly. Then along came a feisty generic maker called Barr Labs. Their battle gives new meaning to the term 'drug war. 2001. Accessed at http://archive.fortune.com/magazines/fortune/fortune_archive/2001/08/13/308077/index.htm.
29. Sarpatwari A, Kesselheim AS. Ensuring timely approval of generic drugs. Health Affairs Blog. 2015. Retrieved from http://healthaffairs.org/blog/2015/03/24/ensuring-timely-approval-of-generic-drugs/.
30. Brill A. Lost prescription drug savings from use of REMS programs to delay generic market entry. 2014. Matrix Global Advisors, Retrieved from http://www.gphaonline.org/media/cms/REMS_Studyfinal_July2014.pdf.
31. ST Session. H.R.2841. FAST Generics Act of 2015. 2015. Retrieved from https://www.congress.gov/114/bills/hr2841/BILLS-114hr2841ih.pdf.
32. Anonymous. Fast generics act reintroduced in congress. 2015. Retrieved from http://www.pharmacytimes.com/publications/issue/2015/september2015/fast-generics-act-reintroduced-in-congress.
33. Kaló Z, Holtorf AP, Alfonso-Cristancho R, Shen J, Ágh T, Inotai A, Brixner D. Need for multicriteria evaluation of generic drug policies. Value Health. 2015;18(2):346-51.
34. Survey of Pharmacy Law - 2015. Mount prospect. IL: National Association of Boards of Pharmacy; 2014.
35. Boehm G, Yao L, Han L, Zheng Q. Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984. Acta Pharm Sin B. 2013;3(5):297-311.
36. U.S. Food and Drug Administration, Lionberger R. GDUFA regulatory science update. GPhA annual meeting. 2015. Retrieved from http://www.fda.gov/downloads/forindustry/userfees/genericdruguserfees/ucm434325.pdf.